Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Drugs & Aging
Published in: Drugs & Aging 4/2008

01-04-2008 | Therapy In Practice

Diagnosis and Treatment of Giant Cell Arteritis

Authors: Dr Fabrizio Cantini, Laura Niccoli, Carlotta Nannini, Michele Bertoni, Carlo Salvarani

Published in: Drugs & Aging | Issue 4/2008

Login to get access

Abstract

Giant cell arteritis (GCA) is a chronic granulomatous vasculitis of unknown aetiology occurring in the elderly. It affects the cranial branches of the arteries originating from the aortic arch and is usually associated with markedly elevated acute-phase reactants. In 10–15% of cases the extra-cranial branches of the aortic arch are involved. GCA is closely related to polymyalgia rheumatica (PMR), although the relationship between the two disorders is still unclear. New-onset headache, scalp tenderness, jaw claudication, temporal artery abnormalities on physical examination, visual symptoms and associated PMR represent the most typical and frequent features of the disease. Systemic manifestations, including fever, anorexia and weight loss, are observed in 50% of cases. Less frequent manifestations are related to the central or peripheral nervous systems, the respiratory tract and extra-cranial large-vessel involvement. As GCA is characterized by a wide spectrum of clinical manifestations, it is important to recognize the different onset patterns of the disease and related diagnostic steps. The diagnosis is relatively straightforward in the presence of typical cranial manifestations, but it may be challenging in the case of a normal erythrocyte sedimentation rate, occult GCA or in patients with isolated extra-cranial features. Temporal artery biopsy still represents the gold standard for diagnosis, while the role of ultrasonography, high-resolution magnetic resonance imaging and positron emission tomography should be better addressed. Corticosteroids remain the therapy of choice. Data supporting the usefulness of antiplatelet agents and anticoagulants combined with corticosteroids to prevent ischaemic complications as well as the corticosteroidsparing effect of methotrexate and anti-tumour necrosis factor-α drugs are limited and non-conclusive.
Literature
1.
Salvarani C, Cantini F, Boiardi L, et al. Polymyalgia rheumatica and giant cell arteritis. N Engl J Med 2002 Jul 25; 347(4): 261–71PubMedCrossRef
2.
Portioli I. The history of polymyalgia rheumatica/giant cell arteritis. Clin Exp Rheumatol 2000 Jul–Aug; 18 (4 Suppl. 20): S1–3PubMed
3.
Hutchinson J. Diseases of the arteries: on a peculiar form of thrombotic arteritis of the aged which is sometimes productive of gangrene. Arch Surg 1890; 1: 323–9
4.
Horton BT, Magath TB, Brown GE. An undescribed form of arteritis of the temporal vessels. Mayo Clin Proc 1932; 7: 700–1
5.
6.
Lie JT. Illustrated histopathologic classification criteria for selected vasculitis syndromes. Arthritis Rheum 1990 Aug; 33(8): 1074–87PubMedCrossRef
7.
Smeeth L, Cook C, Hall AJ. Incidence of diagnosed polymyalgia rheumatica and temporal arteritis in the United Kingdom, 1990–2001. Ann Rheum Dis 2006; 65: 1093–8PubMedCrossRef
8.
Salvarani C, Gabriel SE, O’Fallon WM, et al. The incidence of giant cell arteritis in Olmsted County, Minnesota: apparent fluctuations in a cyclic pattern. Ann Intern Med 1995; 123: 192–4PubMed
9.
Doran MF, Crowson CS, O’Fallon WM, et al. Trends in the incidence of PMR over a 30 year period in Olmsted County, Minnesota, USA. J Rheumatol 2002; 29: 1694–7PubMed
10.
Gay MA, Miranda-Filloy JA, Lopez-Diaz MJ, et al. Giant cell arteritis in northwestern Spain: a Gonzalez 25-year epidemiologic study. Medicine (Baltimore) 2007 Mar; 86(2): 61–8CrossRef
11.
Salvarani C, Macchioni P, Zizzi F, et al. Epidemiologic and immunogenetic aspects of polymyalgia rheumatica and giant cell arteritis in northern Italy. Arthritis Rheum 1991; 34: 351–6PubMedCrossRef
12.
Kobayashi S, Yano T, Matsumoto Y, et al. Clinical and epidemiologic analysis of giant cell (temporal) arteritis from a nationwide survey in 1998 in Japan: the first government-supported nationwide survey. Arthritis Rheum 2003 Aug 15; 49(4): 594–8PubMedCrossRef
13.
Gonzalez EB, Varner WT, Lisse JR, et al. Giant-cell arteritis in the southern United States: an 11-year retrospective study from the Texas Gulf Coast. Arch Intern Med 1989 Jul; 149(7): 1561–5PubMedCrossRef
14.
Lam BL, Wirthlin RS, Gonzalez A, et al. Giant cell arteritis among Hispanic Americans. Am J Ophthalmol 2007 Jan; 143(1): 161–3PubMedCrossRef
15.
16.
Wilske KR, Healey LA. Polymyalgia rheumatica: a manifestation of systemic giant cell arteritis. Ann Intern Med 1965; 66: 77–91
17.
Boesen P, Sorenson SF. Giant cell arteritis, temporal arteritis, and polymyalgia rheumatica. Arthritis Rheum 1987 Mar; 30(3): 294–9PubMedCrossRef
18.
Bengtsson BA, Malmvall BE. The epidemiology of giant cell arteritis including temporal arteritis and polymyalgia rheumatica. Arthritis Rheum 1981 Jul; 24(7): 899–904PubMedCrossRef
19.
Gonzalez-Gay MA. Giant cell arteritis and polymyalgia rheumatica: two different but often overlapping conditions. Semin Arthritis Rheum 2004 Apr; 33(5): 289–93PubMedCrossRef
20.
Cantini F, Niccoli L, Storri L, et al. Are polymyalgia rheumatica and giant cell arteritis the same disease? Semin Arthritis Rheum 2004 Apr; 33(5): 294–301PubMedCrossRef
21.
Gonzalez-Gay MA, Amoli MM, Garcia-Porrua C, et al. Genetic markers of disease susceptibility and severity in giant cell arteritis and polymyalgia rheumatica. Semin Arthritis Rheum 2003 Aug; 33(1): 38–48PubMedCrossRef
22.
Elling P, Olsson AT, Elling H. Synchronous variations of the incidence of temporal arteritis and polymyalgia rheumatica in different regions of Denmark; association with epidemics of Mycoplasma pneumoniae infection. J Rheumatol 1996 Jan; 23(1): 112–9PubMed
23.
Helling H, Olsson AT, Elling P. Human parvovirus and giant cell arteritis: a selective arteritic impact? Clin Exp Rheumatol 2000; 18 (4 Suppl. 20): S12–4
24.
Cimmino M, Grazi MA, Balistreri M, et al. Increased prevalence of antibodies to adenovirus and respiratory syncytial virus in polymyalgia rheumatica. Clin Exp Rheumatol 1993 May–Jun; 11(3): 309–13PubMed
25.
Wagner A, Gerard HC, Fresemann T, et al. Detection of Chlamydia pneumoniae in giant cell vasculitis and correlation with the topographic arrangement of tissue-infiltrating dendritic cells. Arthritis Rheum 2000 Jul; 43(7): 1543–51PubMedCrossRef
26.
Gabriel SE, Espy M, Erdman DD, et al. The role of parvovirus B19 in the pathogenesis of giant cell arteritis: a preliminary evaluation. Arthritis Rheum 1999 Jun; 42(6): 1255–8PubMedCrossRef
27.
Salvarani C, Farnetti E, Casali B, et al. Detection of parvovirus B19 DNA by polymerase chain reaction in giant cell arteritis: a case-control study. Arthritis Rheum 2002 Nov; 46(11): 3099–101PubMedCrossRef
28.
Regan MJ, Wood BJ, Hsieh YH, et al. Temporal arteritis and Chlamydia pneumoniae: failure to detect the organism by polymerase chain reaction in ninety cases and ninety controls. Arthritis Rheum 2002 Apr; 46(4): 1056–60PubMedCrossRef
29.
Helveg-Larsen J, Tarp B, Obel N, et al. No evidence of parvovirus B19, Chlamydia pneumoniae or human herpes virus infection in temporal artery biopsies in patients with giant cell arteritis. Rheumatology (Oxford) 2002 Apr; 41(4): 445–9CrossRef
30.
Duhaut P, Bosshard S, Calvet A, et al. Giant cell arteritis, polymyalgia rheumatica and viral hypotheses: a multicentric, prospective case-control study. J Rheumatol 1999 Feb; 26(2): 361–9PubMed
31.
Narvaez J, Clavaguera MT, Nolla-Solé JM, et al. Lack of association between infection and onset of PMR. J Rheumatol 2000 Apr; 27(4): 953–7PubMed
32.
Weyand CM, Goronzy JJ. Arterial wall injury in giant cell arteritis. Arthritis Rheum 1999 May; 42(5): 844–53PubMedCrossRef
33.
Weyand CM, Goronzy JJ. Giant-cell arteritis and polymyalgia rheumatica. Ann Intern Med 2003 Sep; 139(6): 505–15PubMed
34.
Calamia KT, Hunder GG. Clinical manifestations of giant cell (temporal) arteritis. Clin Rheum Dis 1980; 6: 389–403
35.
Calamia KT, Hunder GG. Giant cell arteritis (temporal arteritis) presenting as fever of undetermined origin. Arthritis Rheum 1981 Nov; 24(11): 1414–8PubMedCrossRef
36.
Huston KA, Hunder GG, Lie JT, et al. Temporal arteritis: a 25-year epidemiologic, clinical and pathologic study. Ann Intern Med 1978 Feb; 88(2): 162–7PubMed
37.
Smetana GW, Shmerling RH. Does this patient have temporal arteritis? JAMA 2002 Jan; 287(1): 92–101PubMedCrossRef
38.
Soderstrom CW, Seehafer JR. Bilateral scalp necrosis in temporal arteritis. Am J Med 1976 Oct; 61(4): 541–6PubMedCrossRef
39.
Currey J. Case report: scalp necrosis in giant cell arteritis and review of the literature. Br J Rheumatol 1997 Jul; 36(7): 814–6PubMedCrossRef
40.
Nir-Paz R, Gross A, Chajek-Shaul T. Reduction of jaw opening (trismus) in giant cell arteritis. Ann Rheum Dis 2002 Mar; 61(3): 832–3PubMedCrossRef
41.
Aiello PD, Trautmann JC, McPhee TJ, et al. Visual prognosis in giant cell arteritis. Ophthalmology 1993 Apr; 100(4): 550–6PubMed
42.
Gonzalez-Gay MA, Blanco R, Rodriguez-Valverde V, et al. Permanent visual loss and cerebrovascular accidents in giant cell arteritis: predictors and response to treatment. Arthritis Rheum 1998 Aug; 41(8): 1497–504PubMedCrossRef
43.
Hayreh SS, Podhajsky PA, Zimmerman B. Ocular manifestations of giant cell arteritis. Am J Ophthalmol 1998 Apr; 125(4): 742–4
44.
Gonzalez-Gay MA, Garcia-Porrua C, Llorca J, et al. Visual manifestations of giant cell arteritis: trends and clinical spectrum in 161 patients. Medicine (Baltimore) 2000 Sep; 79(5): 283–92CrossRef
45.
Nesher G, Nesher R, Rozenman Y, et al. Visual hallucinations in giant cell arteritis: association with visual loss. J Rheumatol 2001 Apr; 28(4): 2046–8PubMed
46.
Caselli R, Hunder GG, Whisnant JP. Neurologic disease in biopsy-proven giant cell (temporal) arteritis. Neurology 1988 Mar; 38(3): 352–9PubMedCrossRef
47.
Caselli R, Daube JR, Hunder GG, et al. Peripheral neuropathic syndromes in giant cell (temporal) arteritis. Neurology 1988 May; 38(5): 685–9PubMedCrossRef
48.
Larson TS, Hall S, Hepper NG, et al. Respiratory tract symptoms as a clue to giant cell arteritis. Ann Intern Med 1984 Nov; 101(5): 594–7PubMed
49.
Klein RG, Hunder GG, Stanson AW, et al. Large artery involvement in giant cell (temporal) arteritis. Ann Intern Med 1975 Dec; 83(6): 806–12PubMed
50.
Brack A, Martinez-Taboada V, Stanson A, et al. Disease pattern in cranial and large-vessel giant cell arteritis. Arthritis Rheum 1999 Feb; 42(2): 311–7PubMedCrossRef
51.
Bongartz T, Matteson E. Large-vessel involvement in giant cell arteritis. Curr Opin Rheumatol 2006 Jan; 18(1): 10–7PubMedCrossRef
52.
Evans JM, O’Fallon WM, Hunder GG. Increased incidence of aortic aneurysm and dissection in giant cell (temporal) arteritis. Ann Intern Med 1995 Apr; 122(7): 502–7PubMed
53.
Gonzalez-Gay MA, Garcia-Porrua C, Pineiro A, et al. Aortic aneurysm and dissection in patients with biopsy-proven giant cell arteritis from northwestern Spain: a population-based study. Medicine (Baltimore) 2004 Nov; 83(6): 335–41CrossRef
54.
Nuenninghoff DM, Hunder GG, Christianson TJH, et al. Incidence and predictors of large-artery complication (aortic aneurysm, aortic dissection, and/or large-artery stenosis) in patients with giant cell arteritis. Arthritis Rheum 2003 Dec; 48(12): 3522–31PubMedCrossRef
55.
56.
Chuang T-Y, Hunder GG, Ilstrup DM, et al. Polymyalgia rheumatica: a 10-year epidemiologic and clinical study. Ann Intern Med 1982 Nov; 97(5): 672–80PubMed
57.
Healey LA. Long-term follow-up of polymyalgia rheumatica: evidence for synovitis. Semin Arthritis Rheum 1984 May; 13(4): 322–8PubMedCrossRef
58.
Salvarani C, Cantini F, Olivieri I, et al. Polymyalgia rheumatica: a disorder of extraarticular synovial structures? J Rheumatol 1999 Mar; 26(3): 517–21PubMed
59.
Salvarani C, Cantini F, Macchioni L, et al. Distal musculoskeletal manifestations in polymyalgia rheumatica: a prospective follow-up study. Arthritis Rheum 1998 Jul; 41(7): 1221–6PubMedCrossRef
60.
Blockmans D, de Ceuninck L, Vanderschueren S, et al. Repetitive 18F-fluorodeoxyglucose positron emission tomography in giant cell arteritis: a prospective study of 35 patients. Arthritis Rheum 2006 Feb; 55(1): 131–7PubMedCrossRef
61.
Salvarani C, Cantini F, Olivieri I, et al. Proximal bursitis in active polymyalgia rheumatica. Ann Intern Med 1997 Jul; 127(1): 27–31PubMed
62.
Cantini F, Salvarani C, Olivieri I, et al. Shoulder ultrasonography in the diagnosis of polymyalgia rheumatica: a case-control study. J Rheumatol 2001 May; 28(5): 1049–55PubMed
63.
Cantini F, Salvarani C, Olivieri I, et al. Inflamed shoulder structures in polymyalgia rheumatica with normal erythrocyte sedimentation rate. Arthritis Rheum 2001 May; 44(5): 1155–9PubMedCrossRef
64.
Cantini F, Niccoli L, Nannini C, et al. Inflammatory changes of hip synovial structures in polymyalgia rheumatica. Clin Exp Rheumatol 2005 Jul–Aug; 23(4): 462–8PubMed
65.
Salvarani C, Hunder GG. Giant cell arteritis with low erythrocyte sedimentation rate: frequency of occurrence in a population-based study. Arthritis Rheum 2001 Apr; 45(2): 140–5PubMedCrossRef
66.
Salvarani C, Cimino L, Macchioni P, et al. Risk factors for visual loss in an Italian population-based cohort of patients with giant cell arteritis. Arthritis Rheum 2005 Apr; 53(2): 293–7PubMedCrossRef
67.
Salvarani C, Gabriel SE, O’Fallon WM, et al. Epidemiology of polymyalgia rheumatica in Olmsted County, Minnesota, 1970–1991. Arthritis Rheum 1995 Mar; 38(3): 369–73PubMedCrossRef
68.
Franzén P, Sutinen S, Von Knorring J. Giant cell arteritis and polymyalgia rheumatica in a region of Finland: an epidemiologic, clinical and pathologic study, 1984–1988. J Rheumatol 1992 Feb; 19(2): 273–80PubMed
69.
Salvarani C, Silingardi M, Ghirarduzzi A, et al. Is duplex ultrasonography useful for the diagnosis of giant cell arteritis? Ann Intern Med 2002 Aug; 137(4): 232–8PubMed
70.
Gonzalez-Gay MA, Lopez-Diaz MJ, Barros S, et al. Giant cell arteritis: laboratory tests at the time of diagnosis in a series of 240 patients. Medicine (Baltimore) 2005 Sep; 84(5): 277–90CrossRef
71.
Schmidt WA, Kraft HE, Vorpahl K, et al. Color duplex ultrasonography in the diagnosis of temporal arteritis. N Engl J Med 1997; 337: 1336–42PubMedCrossRef
72.
Gonzalez-Gay MA, Garcia-Porrua C, Amor-Dorado JC, et al. Fever in biopsy-proven giant cell arteritis: clinical implications in a defined population. Arthritis Rheum 2004 Aug 15; 51(4): 652–5PubMedCrossRef
73.
Woolery WA, Franco FR. Fever of unknown origin: keys to determining the etiology in older patients. Geriatrics 2004 Oct; 59(10): 41–5PubMed
74.
Hayreh SS, Podhajsky PA, Zimmerman B. Occult giant cell arteritis: ocular manifestations. Am J Ophthalmol 1998 Apr; 125(4): 521–6PubMedCrossRef
75.
Weiss LB, Gonzalez E, Miller SB, et al. Severe anemia as the presenting manifestation of giant cell arteritis. Arthritis Rheum 1995 Mar; 38(3): 434–6PubMedCrossRef
76.
Bablekos GD, Michaelidis SA, Karachalios GN, et al. Pericardial involvement as an atypical manifestation of giant cell arteritis: report of a clinical case and literature review. Am J Med Sci 2006 Oct; 332(4): 198–204PubMedCrossRef
77.
Gur H, Ehrenfeld M, Izsak E. Pleural effusion as a presenting manifestation of giant cell arteritis. Clin Rheumatol 1996 Mar; 15(2): 200–3PubMedCrossRef
78.
Karagiannis A, Mathiopoulou L, Tziomalos K, et al. Dry cough as first manifestations of giant cell arteritis. J Am Geriatr Soc 2006 Dec; 54(12): 1957–8PubMedCrossRef
79.
Lazaridis C, Torabi A, Cannon S. Bilateral third nerve palsy and temporal arteritis. Arch Neurol 2005 Nov; 62(11): 1766–8PubMedCrossRef
80.
Nesher G, Rosenberg P, Shorer Z, et al. Involvement of the peripheral nervous system in temporal arteritis-polymyalgia rheumatica: report of 3 cases and review of the literature. J Rheumatol 1987 Apr; 14(2): 358–60PubMed
81.
Patel RK, Carrick K. Giant cell arteritis of the female genital tract: report of a case and review of the literature. South Med J 2005 Apr; 98(4): 469–71PubMedCrossRef
82.
Hunder GG, Bloch DA, Michel BA, et al. The American College of Rheumatology 1990 criteria for the classification of giant cell (temporal) arteritis. Arthritis Rheum 1990 Aug; 33(8): 1122–8PubMedCrossRef
83.
Weyand CM, Fullbright JW, Hunder GG, et al. Treatment of giant cell arteritis: interleukin-6 as a biologic marker of disease activity. Arthritis Rheum 2000 May; 43(5): 1041–8PubMedCrossRef
84.
Cantini F, Salvarani C, Olivieri I, et al. Erythrocyte sedimentation rate and C-reactive protein in the evaluation of disease activity and severity in polymyalgia rheumatica: a prospective, follow-up study. Semin Arthritis Rheum 2000 Aug; 30(1): 17–24PubMedCrossRef
85.
Parikh M, Miller NR, Lee AG, et al. Prevalence of normal C-reactive protein with elevated erythrocyte sedimentation rate in biopsy-proven giant cell arteritis. Ophthalmology 2006 Oct; 113(10): 1842–5PubMedCrossRef
86.
Esteban M-J, Font C, Hernandez-Rodriguez J, et al. Small-vessel vasculitis surrounding a spared temporal artery: clinical and pathologic findings in a series of twenty-eight patients. Arthritis Rheum 2001 Jun; 44(6): 1387–95PubMedCrossRef
87.
Rao JK, Allen NB, Pincus T. Limitations of the 1990 American College of Rheumatology classification criteria in the diagnosis of vasculitis. Ann Intern Med 1998 Sep; 129(5): 345–52PubMed
88.
Gonzalez-Gay MA. The diagnosis and management of patients with giant cell arteritis. J Rheumatol 2005 Jul; 32(7): 1186–8PubMed
89.
Achkar AA, Lie JT, Hunder GG, et al. How does previous corticosteroid treatment affect the biopsy findings in giant cell (temporal) arteritis? Ann Intern Med 1994 Jun; 120(12): 987–92PubMed
90.
Karahaliou M, Vaiopoulos G, Papaspyrou S, et al. Colour duplex sonography of temporal arteries before decision for biopsy: a prospective study in 55 patients with suspected giant cell arteritis. Arthritis Res Ther 2006 Jul; 8(4): R116PubMedCrossRef
91.
Bley TA, Wieben O, Uhl M, et al. High-resolution MRI in giant cell arteritis: imaging of the wall of the superficial temporal artery. AJR Am J Roentgenol 2005 Jan; 184(1): 283–7PubMed
92.
Markl M, Uhl M, Wieben O, et al. High-resolution 3T MRI for the assessment of cervical and superficial cranial arteries in giant cell arteritis. J Magn Reson Imaging 2006 Aug; 24(2): 423–7PubMedCrossRef
93.
Chavaillaz O, Gueddi S, Taylor S, et al. Giant cell arteritis mimicking fever of unknown origin: potential diagnostic role of PET scan. Thromb Haemost 2006 Feb; 95(2): 390–2PubMed
94.
Salvarani C, Gabriel SE, Gertz MA, et al. Primary systemic amyloidosis presenting as giant cell arteritis and polymyalgia rheumatica. Arthritis Rheum 1994 Nov; 37(11): 1621–6PubMedCrossRef
95.
Machado EB, Michet CJ, Ballard DJ, et al. Trends in incidence and clinical presentation of temporal arteritis in Olmsted County, Minnesota, 1950–1985. Arthritis Rheum 1988 Jun; 31(6): 745–9PubMedCrossRef
96.
Hunder GG, Sheps SG, Allen GL, et al. Daily and alternate-day corticosteroid regimens in treatment of giant cell arteritis: comparison in a prospective study. Ann Intern Med 1975 May; 82(5): 613–8PubMed
97.
Mazlumzadeh M, Hunder GG, Easley KA, et al. Treatment of giant cell arteritis using induction therapy with high-dose glucocorticoids: a double-blind, placebo-controlled, randomized prospective clinical trial. Arthritis Rheum 2006 Sep; 54(10): 3310–8PubMedCrossRef
98.
Andersson R, Malmvall B-E, Bengtsson B-A. Long-term corticosteroid treatment in giant cell arteritis. Acta Med Scand 1986; 220(5): 465–9PubMedCrossRef
99.
Gabriel SE, Sunku J, Salvarani C, et al. Adverse outcomes of anti-inflammatory therapy among patients with polymyalgia rheumatica. Arthritis Rheum 1997 Oct; 40(10): 1873–8PubMedCrossRef
100.
Nesher G, Sonnenblick M, Friedlander Y. Analysis of steroid related complications and mortality in temporal arteritis: a 15-year survey of 43 patients. J Rheumatol 1994 Jul; 21(7): 1283–6PubMed
101.
Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis. Arthritis Rheum 2001 Jul; 44(7): 1496–503
102.
Lee MS, Smith SD, Galor A, et al. Antiplatelet and anticoagulant therapy in patients with giant cell arteritis. Arthritis Rheum 2006 Oct; 54(10): 3306–9PubMedCrossRef
103.
Nesher G, Berkun Y, Mates M, et al. Low-dose aspirin and prevention of cranial ischemic complications in giant cell arteritis. Arthritis Rheum 2004 Apr; 50(4): 1332–7PubMedCrossRef
104.
Gonzalez-Gay MA, Pineiro A, Gomez-Gigirey A, et al. Influence of traditional risk factors of atherosclerosis in the development of severe ischemic complications in giant cell arteritis. Medicine (Baltimore) 2004 Nov; 83(6): 342–7CrossRef
105.
Narvaez J, Bernad B, Nolla JM, et al. Statin therapy does not seem to benefit giant cell arteritis. Semin Arthritis Rheum 2007; 36(5): 322–7PubMedCrossRef
106.
Both M, Aries PM, Muller-Hulsbeck S, et al. Balloon angioplasty of arteries of the upper extremities in patients with extracranial giant cell arteritis. Ann Rheum Dis 2006 Sept; 65(9): 1124–30PubMedCrossRef
107.
Jover JA, Hernandez-Garcia C, Morado IC, et al. Combined treatment of giant cell arteritis with methotrexate and prednisone. Ann Intern Med 2001 Jan; 134(2): 106–14PubMed
108.
Hoffman GS, Hellmann DB, Guillevin L, et al. A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. Arthritis Rheum 2002 May; 46(5): 1309–18PubMedCrossRef
109.
Weyand CM, Hicock KC, Hunder GG, et al. Tissue cytokine patterns in polymyalgia rheumatica and giant cell arteritis. Ann Intern Med 1994 Oct; 121(7): 484–91PubMed
110.
Field M, Cook A, Gallagher G. Immuno-localisation of tumor necrosis factor and its receptors in temporal arteritis. Rheumatol Int 1997; 17(3): 113–8PubMedCrossRef
111.
Cantini F, Niccoli L, Salvarani C, et al. Treatment of longstanding active giant cell arteritis with infliximab: report of four cases. Arthritis Rheum 2001 Dec; 44(12): 2933–5PubMedCrossRef
112.
Airo P, Antonioli CM, Vianelli M, et al. Anti-tumour necrosis factor treatment with infliximab in a case of giant cell arteritis resistant to steroid and immunosuppressive drugs. Rheumatology (Oxford) 2002 Mar; 41(3): 347–9CrossRef
113.
Uthman I, Kanj N, Atweh S. Infliximab as monotherapy in giant cell arteritis. Clin Rheumatol 2006 Feb; 25(1): 109–10PubMedCrossRef
114.
Tan AL, Holdsworth J, Pease C, et al. Successful treatment of resistant giant cell arteritis with etanercept. Ann Rheum Dis 2003 Apr; 62(4): 373–4PubMedCrossRef
115.
Ahmed MM, Mubashir E, Hayat S, et al. Treatment of refractory temporal arteritis with adalimumab. Clin Rheumatol 2007 Aug; 26(8): 1353–5PubMedCrossRef
116.
Hoffman GS, Cid MC, Rendt-Zagar KE, et al. Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial. Ann Intern Med 2007 May 1; 146(9): 621–30PubMed
Metadata
Title
Diagnosis and Treatment of Giant Cell Arteritis
Authors
Dr Fabrizio Cantini
Laura Niccoli
Carlotta Nannini
Michele Bertoni
Carlo Salvarani
Publication date
01-04-2008
Publisher
Springer International Publishing
Published in
Drugs & Aging / Issue 4/2008
Print ISSN: 1170-229X
Electronic ISSN: 1179-1969
DOI
https://doi.org/10.2165/00002512-200825040-00002

Other articles of this Issue 4/2008

Drugs & Aging 4/2008 Go to the issue

Review Article

A Systematic Review of Interventions to Improve Medication Taking in Elderly Patients Prescribed Multiple Medications

Therapy In Practice

Scabies Outbreaks in Nursing Homes for the Elderly

Original Research Article

Anaemia and the Risk of Injurious Falls in a Community-Dwelling Elderly Population

Original Research Article

Drug-Drug Interactions in a Geriatric Outpatient Cohort

Original Research Article

Use of Antipsychotics in Older Home Care Patients in Finland

Current Opinion

Use of Transdermal Drug Formulations in the Elderly
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits